JJ
FATE icon

Johnson & Johnson’s Fate Therapeutics FATE Stock Holding History

Johnson & Johnson’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.05M Hold
3,379,064
– – 0.62% 10
2025
Q4 		$3.32M Hold
3,379,064
– – 0.6% 10
2025
Q3 		$4.26M Hold
3,379,064
– – 0.84% 11
2025
Q2 		$3.51M Hold
3,379,064
– – 1.05% 11
2025
Q1 		$2.67M Hold
3,379,064
– – 0.78% 11
2024
Q4 		$5.58M Hold
3,379,064
– – 1.44% 11
2024
Q3 		$11.8M Hold
3,379,064
– – 2.77% 11
2024
Q2 		$11.1M Hold
3,379,064
– – 2.77% 11
2024
Q1 		$24.8M Hold
3,379,064
– – 0.56% 10
2023
Q4 		$12.6M Hold
3,379,064
– – 0.29% 12
2023
Q3 		$7.16M Hold
3,379,064
– – 2.64% 10
2023
Q2 		$16.1M Hold
3,379,064
– – 4.99% 7
2023
Q1 		$19.3M Hold
3,379,064
– – 6.27% 6
2022
Q4 		$34.1M Hold
3,379,064
– – 9.92% 4
2022
Q3 		$75.7M Hold
3,379,064
– – 22.28% 1
2022
Q2 		$83.7M Hold
3,379,064
– – 21.39% 2
2022
Q1 		$131M Hold
3,379,064
– – 24.77% 1
2021
Q4 		$198M Hold
3,379,064
– – 22.51% 2
2021
Q3 		$200M Buy
+3,379,064
New +$265M 17.57% 3

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Johnson & Johnson's FATE Position: Q1 2026 in Review

Johnson & Johnson held its Fate Therapeutics (FATE) position steady in Q1 2026 at 3,379,064 shares worth $4.05M. The position accounts for 0.62% of the portfolio, ranked #10.

Johnson & Johnson first reported a position in FATE in Q3 2021 and has held it in 19 quarters since. The position peaked at $200M in Q3 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Johnson & Johnson held 3,379,064 shares of Fate Therapeutics worth $4.05M as of Q1 2026.
  • Johnson & Johnson left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up 0.62% of Johnson & Johnson's portfolio in Q1 2026, its #10 holding.
  • Johnson & Johnson first reported a position in Fate Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Johnson & Johnson's Fate Therapeutics position peaked at $200M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.